Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Maintains Outperform on Visa, Raises Price Target to $265

Raymond James analyst John Davis maintains Visa (NYSE:V) with a Outperform and raises the price target from $263 to $265.

byBenzinga Newsdesk

January 11, 2022

1 minute read

Raymond James analyst John Davis maintains Visa (NYSE:V) with a Outperform and raises the price target from $263 to $265.

Legal
News

Calithera Bioscience Granted European Patent Titled ‘ARGINASE INHIBITOR COMBINATION THERAPIES’

By Benzinga Newsdesk

Today, 9:24 AM

https://register.epo.org/application?number=EP17801266

CALA

Why Are Rent The Runway Shares Trading Higher Today

By Shivani Kumaresan

Today, 9:24 AM

Jefferies analyst Ashley Helgans initiated coverage of Rent The Runway Inc (NASDAQ:RENT) with a Buy rating and $13 price target, implying an 81%…

RENT

Evercore ISI Group Upgrades Enanta Pharmaceuticals to In-Line, Announces $39 Price Target

By Benzinga Newsdesk

Today, 9:24 AM

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from Underperform to In-Line and announces $39 price target.

ENTA

Armata Pharmaceuticals Announces Clearance Of IND For Prosthetic Joint Infections

By Benzinga Newsdesk

Today, 9:24 AM

Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for

ARMP

Raymond James Maintains Outperform on Visa, Raises Price Target to $265

Related Posts

Calithera Bioscience Granted European Patent Titled ‘ARGINASE INHIBITOR COMBINATION THERAPIES’

Why Are Rent The Runway Shares Trading Higher Today

Evercore ISI Group Upgrades Enanta Pharmaceuticals to In-Line, Announces $39 Price Target

Armata Pharmaceuticals Announces Clearance Of IND For Prosthetic Joint Infections